Tarsus Pharmaceuticals, Inc. TARS AFS and Trading Securities - Unrealized Loss Position (<12 Months) Accumulated Loss
AFS and Trading Securities - Unrealized Loss Position (<12 Months) Accumulated Loss at other companies
Other financials
Where this comes from
Reported directly by Tarsus Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions.
The official record: Tarsus Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Tarsus Pharmaceuticals, Inc.'s afs and trading securities - unrealized loss position (<12 months) accumulated loss.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Tarsus Pharmaceuticals, Inc.'s AFS and trading securities - unrealized loss position (<12 months) accumulated loss?
- Tarsus Pharmaceuticals, Inc. (TARS) reported AFS and trading securities - unrealized loss position (<12 months) accumulated loss of 70 in Q1 2026.
- How has Tarsus Pharmaceuticals, Inc.'s AFS and trading securities - unrealized loss position (<12 months) accumulated loss changed year-over-year?
- Tarsus Pharmaceuticals, Inc.'s AFS and trading securities - unrealized loss position (<12 months) accumulated loss increased by 268.4% year-over-year, from 19 to 70.
- What is the long-term trend for Tarsus Pharmaceuticals, Inc.'s AFS and trading securities - unrealized loss position (<12 months) accumulated loss?
- Over 3 years (2022 to 2025), Tarsus Pharmaceuticals, Inc.'s AFS and trading securities - unrealized loss position (<12 months) accumulated loss has grown at a -33.7% compound annual growth rate (CAGR), from 24 to 7.
- What does AFS and trading securities - unrealized loss position (<12 months) accumulated loss mean?
- The aggregate unrealized loss on available-for-sale and trading securities that have been in a loss position for less than one year. This serves as an indicator of short-term market fluctuations affecting the company's investment portfolio.